Claims for Patent: 7,169,791

Summary for Patent: 7,169,791

Title:	Inhibitors of tyrosine kinases
Abstract:	The invention relates to compounds of formula ##STR00001## wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such a disease.
Inventor(s):	Breitenstein; Werner (Basel, CH), Furet; Pascal (Thann, FR), Jacob; Sandra (Rantzwiller, FR), Manley; Paul William (Arlesheim, CH)
Assignee:	Novartis AG (Basel, CH)
Application Number:	10/520,359
Patent Claims:	1. A compound of formula I wherein ##STR00004## R.sub.1 represents hydrogen, lower alkyl, lower alkoxy-lower alkyl, or benzyl; R.sub.2 represents phenyl substituted by one or two substituents selected from the group consisting of lower alkyl, trifluoro-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl, lower alkylamino-lower alkyl, di-lower alkylamino-lower alkyl, N-cyclohexyl-N-lower alkylamino-lower alkyl, lower alkoxycarbonylpiperidino-lower alkyl, N-lower alkylpiperazino-lower alkyl, lower alkoxycarbonyl-lower alkyl, hydroxy, lower alkoxy, trifluoro-lower alkoxy, 1H-imidazolyl-lower alkoxy, lower alkanoyloxy, benzoyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, lower alkylcarbamoyl, amino, lower alkanoylamino, benzoylamino, amino mono- or disubstituted by lower alkyl, by hydroxy-lower alkyl or by loweralkoxy-lower alkyl, 1H-imidazolyl, lower alkyl-1H-imidazolyl, carboxy-1H-imidazolyl, lower alkyl-estercarboxy-1H-imidazolyl, pyrrolidino, piperidino, piperazino, N-lower alkylpiperazino, morpholino, sulfamoyl, lower alkylsulfonyl, phenyl, pyridyl, halogenyl, or benzoyl; and R.sub.4 represents hydrogen, lower alkyl or halo; or a N-oxide or pharmaceutically acceptable salts thereof. 2. A compound of formula I according to claim 1 wherein R.sub.1 represents hydrogen; R.sub.2 represents phenyl substituted by trifluoremethyl and optionally a further substituent selected from the group consisting of hydroxy-lower alkyl, lower alkylamino, hydroxy-lower alkylamino, di-lower alkylamino, 1H-imidazolyl, lower alkyl-1H-imidazolyl, carbamoyl, lower alkylcarbamoyl, pyrrolidino, piperidino, piperazino, lower alkylpiperazino, morpholino, lower alkoxy, trifluoro-lower alkoxy, phenyl, pyridyl, and halogenyl; R.sub.4 represents methyl; or a N-oxide or pharmaceutically acceptable salts thereof. 3. A compound of formula I according to claim 1 wherein R.sub.1 represents hydrogen; R.sub.2 represents phenyl substituted by 3-trifluoromethyl and optionally a further substituent selected from the group consisting of 1-hydroxy-1-methylethyl, methylamino, ethylamino, 2-hydroxy-1-propylamino, 2-hydroxy-2-propylamino, diethylamino, 1H-imidazolyl, 2- and 4-methyl-1H-imidazolyl, carbamoyl, methylcarbamoyl, pyrrolidino, piperidino, piperazino, 4-methylpiperazino, morpholino, methoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, phenyl, 2-, 3- and 4-pyridyl, chloro, and fluoro; R.sub.4 represents methyl; or a N-oxide or pharmaceutically acceptable salts thereof. 4. The compound of formula I according to claim 1 wherein R.sub.1 represents hydrogen; R.sub.2 represents 3-(1-hydroxy-1-methylethyl)-5-(trifluoromethyl)phenyl; R.sub.4 represents methyl; or a N-oxide or pharmaceutically acceptable salts thereof. 5. A compound according to claim 1 wherein R.sub.1 is hydrogen; R.sub.2 represents phenyl which is mono- or disubstituted by imidazol-lower alkoxy, lower alkyl amino, trifluoromethyl, hydroxy lower alkyl amino, bis-(lower alkoxy lower alkyl) amino, lower alkyl piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, phenyl, pyridyl, imidazolyl which is unsubstituted or mono- or disubstituted by lower alkyl or N-lower alkyl carbamoyl; R.sub.4 is lower alkyl; or a N-oxide or pharmaceutically acceptable salts thereof. 6. A compound of formula I according to claim 1 wherein R.sub.1 represents hydrogen; R.sub.2 represents phenyl substituted by 3-trifluoromethyl and a further substituent selected from the group consisting of 2-methyl-1H-imidazolyl and 4-methyl-1H-imidazolyl; R.sub.4 represents methyl; or a N-oxide or pharmaceutically acceptable salts thereof. 7. A compound of formula I according to claim 1 wherein R.sub.1 represents hydrogen; R.sub.2 represents phenyl substituted by 5-trifluoromethyl and optionally a further substituent selected from the group consisting of 2,4-dimethyl-1H-imidazolyl, 5-methyl-1H imidazolyl, 2-methoxymethylamino, propoxy, ethoxy, methylaminocarbonyl, benzoyl, 4-methoxy-2-methyl, acetylamino 2,4-dimethyl-1H-imidazolyl, acetic acid ethyl ester, piperidine carboxylic acid ethyl ester; R.sub.4 represents methyl; or a N-oxide or pharmaceutically acceptable salts thereof. 8. 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-im- idazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or pharmaceutically acceptable salts thereof. 9. A process for the synthesis of a compound of the formula ##STR00005## or an N-oxide or a salt thereof, wherein the symbols R.sub.1, R.sub.2 and R.sub.4 are as defined in claim 1, characterized in that a compound of formula II ##STR00006## wherein R.sub.4 is as defined for a compound of formula I, wherein the carboxyl group --COOH is in activated form, is reacted with an amine of the formula III R.sub.1--NH--R.sub.2 (III) wherein R.sub.1 and R.sub.2 are as defined for a compound of the formula I, optionally in the, presence of a dehydrating agent and an inert base and/or a suitable catalyst, and optionally in the presence of an inert solvent; where the above starting compounds II and III may also be present with functional groups in protected form if necessary and/or in the form of salts, provided a salt-forming group is present and the reaction in salt form is possible; any protecting groups in a protected derivative of a compound of the formula I are removed; and, if so desired, an obtainable compound of formula I is converted into another compound of formula I or a N-oxide thereof, a free compound of formula I is converted into a salt, an obtainable salt of a compound of formula I is converted into the free compound or another salt, and/or a mixture of stereoisomeric compounds of formula I is separated into the individual stereoisomers. 10. A pharmaceutical composition comprising as an active ingredient a compound of formula I according to claim 1 or a N-oxide or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier. 11. A method for the treatment of leukaemias which comprises administering a compound of formula I according to claim 1 or a N-oxide or a pharmaceutically acceptable salt thereof.